Improving on this, OliX has developed a proprietary linker chemistry ... a phase 1 treatment for both wet and dry age-related macular degeneration (AMD)—the first intraocular RNAi-therapeutic ...

In its ocular franchise, OliX’s OLX301A is in development for both wet and dry age-related macular degeneration (AMD), which can both lead to vision loss. Dry or atrophic AMD is the most common ...

Olix Pharmaceuticals Inc. walked the talk in realizing a new $630 million licensing deal with Eli Lilly and Co. for its cardiovascular and metabolic disease asset, OLX-702A (OLX-75016), rallying stock ...

Eli Lilly is paying up to $630m for a Phase I metabolic-associated steatohepatitis (MASH) candidate from South Korea-based biotech OliX Pharmaceuticals, diversifying its pipeline for the disease ...